key: cord-0773912-i3uo85vv
authors: Nayak, Kaustuv; Gottimukkala, Kamalvishnu; Kumar, Sanjeev; Reddy, Elluri Seetharami; Edara, Venkata Viswanadh; Kauffman, Robert; Floyd, Katharine; Mantus, Grace; Savargaonkar, Deepali; Goel, Pawan Kumar; Arora, Satyam; Rahi, Manju; Davis, Carl W; Linderman, Susanne; Wrammert, Jens; Suthar, Mehul S; Ahmed, Rafi; Sharma, Amit; Murali-Krishna, Kaja; Chandele, Anmol
title: Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India
date: 2020-09-01
journal: bioRxiv
DOI: 10.1101/2020.08.31.276675
sha: 1a51c60e41a2770a18e45f5f918613bbf1ed971f
doc_id: 773912
cord_uid: i3uo85vv

India is one of the countries most affected by the recent COVID-19 pandemic. Characterization of humoral responses to SARS-CoV-2 infection, including immunoglobulin isotype usage, neutralizing activity and memory B cell generation, is necessary to provide critical insights on the formation of immune memory in Indian subjects. In this study, we evaluated SARS-CoV-2 receptor-binding domain (RBD)-specific IgG, IgM, and IgA antibody responses, neutralization of live virus, and RBD-specific memory B cell responses in pre-pandemic healthy versus convalescent COVID-19 individuals from India. We observed substantial heterogeneity in the formation of humoral and B cell memory post COVID-19 recovery. While a vast majority (38/42, 90.47%) of COVID-19 recovered individuals developed SARS-CoV-2 RBD-specific IgG responses, only half of them had appreciable neutralizing antibody titers. RBD-specific IgG titers correlated with these neutralizing antibody titers as well as with RBD-specific memory B cell frequencies. In contrast, IgG titers measured against SARS-CoV-2 whole virus preparation, which includes responses to additional viral proteins besides RBD, did not show robust correlation. Our results suggest that assessing RBD-specific IgG titers can serve as a surrogate assay to determine the neutralizing antibody response. These observations have timely implications for identifying potential plasma therapy donors based on RBD-specific IgG in resource-limited settings where routine performance of neutralization assays remains a challenge. Importance Our study provides an understanding of SARS-CoV-2-specific neutralizing antibodies, binding antibodies and memory B cells in COVID-19 convalescent subjects from India. Our study highlights that PCR-confirmed convalescent COVID-19 individuals develop SARS-CoV-2 RBD-specific IgG antibodies, which correlate strongly with their neutralizing antibody titers. RBD-specific IgG titers, thus, can serve as a valuable surrogate measurement for neutralizing antibody responses. These finding have timely significance for selection of appropriate individuals as donors for plasma intervention strategies, as well as determining vaccine efficacy.

Our study provides an understanding of SARS-CoV-2-specific neutralizing antibodies, 73 binding antibodies and memory B cells in COVID-19 convalescent subjects from India. Our 74 study highlights that PCR-confirmed convalescent COVID-19 individuals develop SARS-CoV-75

Introduction 81 82 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for 83 the coronavirus disease 2019 pandemic, emerged as a grave public health threat 84 beginning in December 2019(1), paralyzing daily lives and causing economic downturns in 85 many parts of the world. Currently, India is one of the countries most affected with more 86 than 3 million COVID-19 confirmed cases and 60,000 associated deaths (2). 87 88 Intense efforts are underway to develop vaccines and antiviral therapeutics (3-11). These 89 efforts require a detailed understanding of immune correlates of protection, formation of 90 immune memory, and durability of these responses. Additionally, infusion of plasma derived 91 from COVID-19 recovered individuals is also being explored as a treatment strategy (12) (13) (14) (15) (16) (17) (18) (19) (20) . 92

All these efforts require a detailed understanding of humoral immunity, immunoglobulin 93 isotype usage and neutralizing activity following recovery from SARS-CoV-2 infection. 94

Moreover, given that many of the SARS-CoV-2 neutralizing epitopes are located in the viral 95 receptor binding domain (RBD) of the Spike (S) protein (21) (22) (23) (24) (25) (26) (27) (28) (29) Institutional ethical boards approved the study. Informed consent was obtained prior to 119 inclusion in the study. All subjects (mean age 39.4 years, range 15 -70 years) were SARS-120

CoV-2 PCR positive at the time of initial diagnosis, and were PCR negative when recruited for 121 this study at 3.6 -12 weeks post initial diagnosis (Table 1) . Samples collected from healthy 122 adult blood bank donors in the year 2018 are included as pre-pandemic controls. 123

SARS-CoV-2 specific rRT-PCR was performed as per the Indian government guidelines for 125 COVID-19 diagnosis. Nasopharyngeal and throat swabs were collected in viral transport 126 medium (VTM) (HiMedia, #AL 167)) and transported to the testing laboratory maintaining 127 cold chain. All the samples were subjected to the first line screening assay or the 'e' gene 128 assay as per the guidelines (30). Samples reactive by the first line assay were subjected to 129 the RdRp gene assay (Invitrogen SuperScript™ III Platinum® One-Step Quantitative Kit (Cat. 130 No.11732088). Samples reactive for both the genes were labeled positive, while samples 131 reactive to 'e' gene only were considered indeterminate and were subjected to repeat 132 sampling. The same protocol was used to verify that the subjects were PCR negative at the 133 time of recruitment for this study. 134

Recombinant SARS-CoV-2 RDB gene was cloned, expressed, purified and standard direct 136

ELISAs were performed as previously described (31). Briefly, purified RBD was coated on 137

MaxiSorp plates (Thermo Fisher, #439454) at a concentration of 1 ug/mL in 100 uL 138 phosphate-buffered saline (PBS) at 4 o C overnight. The plates were washed extensively with 139 PBS containing 0.05% Tween-20. Three-fold serially diluted plasma samples were added to 140 the plates and incubated at room temperature for 1hr. After incubation, the plates were 141 washed and the SARS-CoV-2 RBD specific IgG, IgM, IgA signals were detected by incubating 142 with horseradish peroxidase (HRP) conjugated -anti-human IgG (Jackson ImmunoResearch 143

Labs, #109-036-098), IgM (Jackson ImmunoResearch Labs, #109-036-129), or IgA (Jackson 144

ImmunoResearch Labs, #109-036-011). Plates were then washed thoroughly and developed 145 with o-phenylenediamine (OPD) substrate (Sigma, #P8787) in 0.05M phosphate-citrate 146 buffer (Sigma, #P4809) pH 5.0, containing with 0.012% hydrogen peroxide (Fisher Scientific, 147 #18755) just before use. Absorbance was measured at 490 nm. 148

Purified RBD protein (100 ug) was labeled with Alexa Fluor 488 using microscale protein 150 labeling kit (Life Technologies, #A30006) as per manufacturer's protocol. PBMC's were 151 stained with RBD-Alexa Fluor 488 for 1 hour at 4 o C, followed by washing with PBS containing 152 0.25% FBS, and incubation with efluor780 Fixable Viability (Live Dead) dye (Life 153

Technologies, #65-0865-14) and anti-human CD3, CD19, CD27, CD38 and IgD antibodies (BD 154

Biosciences) for 30 minutes. Cells were washed twice with FACS buffer and acquired on BD 155 LSR Fortessa X20. Data was analyzed using FlowJo software 10. SARS-CoV-2 RBD-specific 156 memory B cells were identified in cells positive for CD19, CD20, CD27 that were negative for 157 IgD and CD3. 158 159 IgG ELISA for SARS-CoV-2 whole virus preparation 160 SARS-CoV-2 antigen specific IgG was detected using a commercially available assay (COVID-161

Kavach ELISA tests kit, Zydus diagnostics), which measures responses to antigen 162 concentrated from gamma-irradiated SARS-CoV-2-infected tissue culture fluid as per the 163 manufacturer's instructions (32, 33) . 164

Neutralization titers to SARS-CoV-2 were determined as previously described (31). Briefly 166 infectious clone of the full-length mNeonGreen SARS-CoV-2 (2019-nCoV/USA_WA1/2020) 167 was used to test heat-inactivated COVID-19 convalescent samples and healthy donor 168 samples (pre-pandemic). Heat-inactivated serum was serially diluted three-fold in duplicate 169 starting at a 1:20 dilution in a 96-well round-bottom plate and incubated between 750 FFU 170 of ic-SARS-CoV-2-mNG for 1 h at 37°C. This antibody-virus mixture was transferred into the 171 wells of a 96-well plate that had been seeded with Vero-E6 cells the previous day at a 172 concentration of 2.5× 10 4 cells/well. After 1 hour, the antibody-virus inoculum was removed 173 and 0.85% methylcellulose in 2% FBS containing DMEM was overlaid onto the cell 174 monolayer. Cells were incubated at 37°C for 24 hours. Cells were washed three times with 175 1XPBS (Corning Cellgro) and fixed with 125 µl of 2% paraformaldehyde in PBS (Electron 176

Microscopy Sciences) for 30 minutes. Following fixation, plates were washed twice with 1x 177 PBS and imaged on an ELISPOT reader (CTL Analyzer). Foci were counted using Viridot (34) 178 (counted first under the "green light" setting followed by background subtraction under the 179 "red light" setting). FRNT-mNG50 titers were calculated by non-linear regression analysis 180 using the 4PL sigmoidal dose curve equation on Prism 8 (Graphpad Software). 181

Neutralization titers were calculated as 100% x [1-(average foci in duplicate wells incubated 182 with the specimen) ÷ (average number of foci in the duplicate wells incubated at the highest 183 dilution of the respective specimen). 184

Statistical analysis was performed using GraphPad prism 8.0 software. Non-parametric t test 186 (Mann-Whitney) was used to calculate the differences between groups. Non-parametric 187

Spearman's correlation coefficient (r) was used to calculate correlation between groups. 188 A p value of <0.05 was considered as significant. 

The demographic profile of COVID-19 recovered individuals recruited for this study is shown 194

in Table 1 . All subjects were at least 3.6 weeks past their initial SARS-CoV-2 positive 195 diagnosis. RBD-specific ELISA curves for IgG, IgA and IgM at different dilutions of plasma in 196 pre-pandemic healthy versus COVID-19 recovered individuals are shown in Figure 1 . specific responses were highly elevated in COVID-19 recovered individuals as compared to 198 pre-pandemic healthy controls (Figure 1A ,B,C, left versus middle panels). Titers of IgG, 199 IgA and IgM in the COVID-19 recovered individuals showed substantial inter-individual 200 variation (Figure 1 A, B, C, right panel) -with IgG endpoint titers ranging from below 201 detection to 24484 (2000+619); IgA titers from below detection to 5686 (386+136) and IgM 202 titers from below detection to 2958 (515+90). Four individuals had undetectable RBD-203 specific IgG and IgA titers. One of these individuals was also below detection for IgM (Table  204 2). Inter-individual heterogeneity was not related to the age of the individuals (Figure 2A ) 205 or the number of days that elapsed between PCR confirmation of infection and sample 206 collection ( Figure 2B) . 207 208

To assess plasma neutralizing titers from COVID-19 convalescent individuals, we performed 210 a live virus neutralization assay using a focus-reduction neutralization mNeonGreen (FRNT-211 mNG) assay (31). The neutralizing activity at different dilutions of plasma for pre-pandemic 212 healthy individuals ( Figure 3A ) and COVID-19 recovered individuals is shown in (Figure  213 3B). Figure 3C shows FRNT-mNG50 titers calculated based on the plasma dilution that 214 neutralized 50% of the virus. While all pre-pandemic healthy individuals had undetectable 215 FRNT-mNG50 titers, only half of the COVID-19 recovered individuals showed 50% or more 216 neutralization even at a 1:20 dilution of plasma. Similar to RBD-specific IgG titers, the FRNT-217 mNG50 titers were heterogeneous with the latter reaching titers as high as 682 ( Figure 3C) . 

IgG responses measured using this test. We observed that, of the 42 COVID-19 recovered 232 individuals tested, 33 were IgG positive whereas 9 were below the assay cut off ( Figure 5A) . 233

Of the 9 individuals that were below cut off, 4 also tested negative by the RBD-specific IgG 234 ELISA ( Table 2 ). All of the samples from the pre-pandemic healthy individuals were below 235 the limit of detection using both the ELISA methods. Most importantly, the IgG values 236 obtained by whole virus-based ELISA did not show as robust a correlation (r=0.56) with 237 neutralizing antibody titers ( Figure 5B ) as compared to those observed with RBD-specific 238

IgG titers (r=0.83) (Figure 4, left graph) . 239 240

While circulating neutralizing antibodies help prevent re-infection by viruses, memory B 242 cells allow for rapid production of new antibodies in case of re-infection. To address whether 243 the COVID-19 recovered individuals generated memory B cells, we enumerated RBD-specific 244 memory B cells using fluorescently-conjugated RBD antigen. An example of the flow 245 cytometric gating strategy and RBD staining among the gated memory B cells is shown in 246 Figure 6A and 6B. Figure 6C shows the frequency of RBD-specific memory B cells in a 247 subset of the individuals where sufficient PBMCs were available. Though we found that there 248 was substantial inter-individual variation in the frequency of SARS-CoV-2 RBD-specific 249 memory B cells, their frequencies modestly correlated with RBD-specific IgG titers. host genetic factors (50-52) and disease severity (53, 54) . This is consistent with previous 284 studies that show relatively higher neutralizing antibodies in COVID-19 hospitalized patients 285 during the acute febrile phase, or in recovered individuals that were previously hospitalized 286 with severe COVID-19 disease (53, 54). It is noteworthy that the COVID-19 recovered 287 individuals from our study had mild to moderate symptoms during the initial diagnosis. In 288 light of these studies, our findings warrant future studies to seek an understanding of 289 whether the individuals that have generated low or no neutralizing antibodies, IgG titers or 290 memory B cells past recovery will be protected if they were re-exposed to SARS-CoV-2 or a 291 related virus. 

Timeline: WHO's COVID-19 response. 379 2. Ministry of Health and Family Welfare GoI. 2020. COVID-19 INDIA as on

Vaccine Candidates against Coronavirus 382 Infections. Where Does COVID-19 Stand? Viruses 12

SARS-CoV-2 Vaccines: Status Report

Approaches and Challenges in SARS-CoV-2 Vaccine 386 Development

Promising Agent for the Treatment of COVID-19

Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease

Emerging 392 Therapeutic Modalities against COVID-19

Current 394 coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: 395 An updated review until

Utilizing drug repurposing against COVID-19 -Efficacy, 397 limitations, and challenges

Current updates on the European and WHO 400 registered clinical trials of coronavirus disease 2019 (COVID-19)

Risk-benefit analysis on the 404 clinical significance of convalescent plasma therapy in the management of COVID-19

Effectiveness of convalescent plasma therapy in severe COVID-411 19 patients

Convalescent Plasma Therapy for 413 COVID-19: State of the Art

Convalescent 415 Plasma Therapy on Patients with Severe or Life-Threatening COVID-19: A Metadata 416 Analysis

Treatment of COVID-19 Patients with Convalescent 420

Plasma Reveals a Signal of Significantly Decreased Mortality

Treatment of 5 Critically Ill Patients With

With Convalescent Plasma

Treatment with 427 convalescent plasma for COVID-19 patients in Wuhan

Treatment With Convalescent Plasma for Critically Ill Patients 431

With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Structures of Human Antibodies 436 Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of 437 Antibodies

Disappearance of antibodies 439 to SARS-associated coronavirus after recovery

441 Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 442 receptor

Potent neutralizing antibodies against 446 multiple epitopes on SARS-CoV-2 spike

COVID-19 448 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-449 CoV-2

2020. A highly specific and sensitive serological 455 assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with 456 neutralization

Structural and Functional Basis of SARS-CoV-2 Entry by 459 Using Human ACE2

Potently neutralizing human antibodies that block SARS-CoV-2 receptor 465 binding and protect animals

Rapid isolation and profiling of a diverse panel 471 of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Standard Operating Procedure For Detection of 2019 novel 474 coronavirus (2019-nCoV) in suspected human cases by rRT-PCR : confirmation assay

Rapid generation of neutralizing antibody responses in COVID-19 481 patients

Bhatnagar 483 S. 2020. Comparative Evaluation of SARS-CoV-2 IgG Assays in India

Covid Support Team: Pawar S 489 PSSVNVMVMBJASPMRKRSDK. 2020. Development of indigenous IgG ELISA for the 490 detection of anti-SARS-CoV-2 IgG

Viridot: An automated virus plaque (immunofocus) counter for the 494 measurement of serological neutralizing responses with application to dengue virus

The neutralizing role of IgM during early 497 Chikungunya virus infection

A cross-reactive human IgA monoclonal 502 antibody blocks SARS-CoV-2 spike-ACE2 interaction

Potent neutralizing serum immunoglobulin A (IgA) in human 505 immunodeficiency virus type 2-exposed IgG-seronegative individuals

Influenza virus-specific neutralizing IgM 509 antibodies persist for a lifetime

A Phase II, Open Label, Randomized Controlled Trial to Assess the 516 Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated 517 Complications in Moderate Disease

FDA. 2020. Recommendations for Investigational COVID-19 Convalescent Plasma

T cell responses in patients with COVID-19

Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and 525 Unexposed Individuals

Ostro 527 R, Banovcin P. 2020. Immune Parameters and COVID-19 Infection -Associations With 528 Clinical Severity and Disease Prognosis

Viral Persistence Induces Antibody 530 Inflation without Altering Antibody Avidity

Initial viral load determines the magnitude of 533 the human CD8 T cell response to yellow fever vaccination

Role of host immune response and viral load in the differential 537 outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. PLoS 538 One 5

Correlation of plasma viral loads and 540 presence of Chikungunya IgM antibodies with cytokine/chemokine levels during 541 acute Chikungunya virus infection

Buying time-the immune system 543 determinants of the incubation period to respiratory viruses

Deciphering the Role of Host Genetics in 546 Susceptibility to Severe COVID-19

New insights into genetic susceptibility of COVID-19: an ACE2 and 549 TMPRSS2 polymorphism analysis

The Role of Host 551 Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic 552 Review of Human Literature

Serologic 554 Response to SARS-CoV-2 in COVID-19 Patients with Different Severity

Antibody Profiles in Mild and Severe Cases of COVID-19